Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2793462 | 1.00 | DDB1 (0.46) | DDB1CRBNIRAK4MAOBHDAC8 | |
| SCHEMBL6412785 | 1.00 | DDB1 (0.46) | DDB1CRBNIRAK4MAOBHDAC8 | |
| SCHEMBL21338622 | 1.00 | DDB1 (0.46) | DDB1CRBNIRAK4MAOBHDAC8 | |
| SCHEMBL22728222 | 0.88 | DDB1 (0.44) | DDB1CRBNIRAK4MAOBHDAC8 | |
| SCHEMBL21338548 | 0.81 | ACHE (0.44) | IRAK4 | |
| SCHEMBL17137424 | 0.81 | ACHE (0.44) | IRAK4 | |
| SCHEMBL18950480 | 0.79 | CYP26A1 (0.40) | DDB1CRBNIRAK4 | |
| SCHEMBL20340657 | 0.79 | CYP26A1 (0.40) | DDB1CRBNIRAK4 | |
| SCHEMBL4293099 | 0.77 | DDB1 (0.46) | DDB1CRBNHDAC8 | |
| SCHEMBL7451040 | 0.77 | DDB1 (0.46) | DDB1CRBNHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER (US) | 2023-10-26 | — | — | US | disclosed |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20200377511-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2020-12-03 | — | — | US | disclosed |
| US-20200377511-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2020-12-03 | — | — | US | disclosed |
| US-20160347760-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160347760-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-9458168-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458168-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458168-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2016-10-04 | — | — | US | disclosed |
| WO-2015150995-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015150995-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150284405-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284405-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284405-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347760-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | DDB1 4483/4885CRBN 1397/4885IRAK4 4619/4885 |
| US-20150284405-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | DDB1 4483/4885CRBN 1397/4885IRAK4 4619/4885 |
| US-20200377511-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | DDB1 4483/4885CRBN 1397/4885IRAK4 4619/4885 |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | TTR, TYR, ABL1 | DDB1 4117/4885CRBN 1390/4885IRAK4 1318/4885 |
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | TTR, TYR, ABL1 | DDB1 4117/4885CRBN 1390/4885IRAK4 1318/4885 |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | DDB1 4483/4885CRBN 1397/4885IRAK4 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.